Mark Pegram, MD
It is an exciting time in drug development for patients with HER2-positive breast cancer, which is leading to new therapeutic strategies and FDA approvals, says Mark D. Pegram, MD.
on Breast Cancer, Pegram, associate director for clinical research and director of the breast oncology program at Stanford Women’s Cancer Center, discussed the evolving treatment paradigm of HER2-positive breast cancer.
OncLive: Please provide an overview of your presentation on HER2-positive breast cancer.
: It is a very exciting time in drug development for patients with HER2-positive breast cancer. We have seen recent FDA approvals for new approaches to treat patients with early-stage HER2-positive breast cancer.
... to read the full story